16:58 EST MiNK Therapeutics (INKT) files $150M mixed securities shelf
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
- MiNK Therapeutics reports updated clinical results on agenT-797
- MiNK Therapeutics Appoints Dr. John Holcomb as Director
- MiNK Therapeutics appoints John Holcomb to board of directors
- MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases